Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

被引：12

作者：

Sangro, B. ^{[1
,2
,3
]}

Chan, S. ^{[4
]}

Kelley, R. ^{[5
]}

Lau, G. ^{[6
]}

Kudo, M. ^{[7
]}

Sukeepaisarnjaroen, W. ^{[8
]}

De Toni, E. ^{[9
]}

Furuse, J. ^{[10
]}

Kang, Y. ^{[11
]}

Galle, P. ^{[12
]}

Rimassa, L. ^{[13
]}

Heurgue, A. ^{[14
]}

Tam, V. ^{[15
]}

Dao, T. ^{[16
]}

Thungappa, S. ^{[17
]}

Breder, V. ^{[18
]}

Ostapenko, Y. ^{[19
]}

Reig, M. ^{[20
]}

Makowsky, M. ^{[21
]}

Gupta, C. ^{[22
]}

Negro, A. ^{[23
]}

Abou-Alfa, G. ^{[24
,25
]}

机构：

[1] Clin Univ Navarra, Liver Unit, Pamplona, Spain

[2] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain

[3] CIBEREHD, Pamplona, Spain

[4] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China

[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[6] Human & Hlth Med Grp, Human & Hlth Clin Trial Ctr, Hong Kong, Peoples R China

[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[8] Khon Kaen Univ, Song klanagarind Hosp, Dept Med, Fac Med, Khon Kaen, Thailand

[9] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany

[10] Kanagawa Canc Ctr, Yokohama, Japan

[11] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[12] Univ Med Ctr, Dept Internal Med 1, Mainz, Germany

[13] Humanitas Univ, IRCCS Humanitas Res Hosp, Pieve Emanuele & Humanitas Canc Ctr, Dept Biomed Sci, Milan, Italy

[14] Robert Debre Hosp, Dept Hepato Gastroenterol, Reims, France

[15] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada

[16] Natl Canc Hosp, Dept Optimal Therapy, Canc Res & Clin Trials Ctr, Hanoi, Vietnam

[17] Hlth Care Global Enterprises Ltd, Bangalore, India

[18] NN Blokhin Russian Canc Res Ctr, Chemotherapy Unit, Moscow, Russia

[19] Natl Canc Inst, Dept Minimally Invas & Endoscop Surg, Intervent Radiol, Kiev, Ukraine

[20] Univ Barcelona, Hosp Clin IDI BAPS, Liver Unit, Barcelona Clin Liver Canc BCLC, Barcelona, Spain

[21] AstraZeneca, Late Stage Dev, Oncol R&D, Gaithersburg, MD USA

[22] AstraZeneca, Late Oncol Stat, Oncol Biometr, Wilmington, DE USA

[23] AstraZeneca, Gaithersburg, MD USA

[24] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[25] Cornell Univ, Weill Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.487

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SO-15

引用

页码：S168 / S168

页数：1

共 50 条

[1] FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Abou-Alfa, Ghassan K.
Chan, Stephen Lam
Kelley, Kate
Lau, George
Kudo, Masatoshi
Sukeepaisarnjaroen, Wattana
De Toni, Enrico N.
Furuse, Junji
Kang, Yoon Koo
Galle, Peter R.
Rimassa, Lorenza
Heurgue, Alexandra
Tam, Vincent C.
Tu Van Dao
Thungappa, Satheesh Chiradoni
Breder, Valeriy
Ostapenko, Yuriy
Reig, Maria
Makowsky, Mallory
Gupta, Charu
Negro, Alejandra
Sangro, Bruno
[J]. HEPATOLOGY, 2023, 78 : S90 - S91
[2] Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B.
Chan, S. L.
Kelley, R. K.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
Yarchoan, M.
De Toni, E. N.
Furuse, J.
Kang, Y. K.
Galle, P. R.
Rimassa, L.
Heurgue, A.
Tam, V. C.
Van Dao, T.
Thungappa, S. C.
Breder, V.
Ostapenko, Y.
Reig, M.
Makowsky, M.
Paskow, M. J.
Gupta, C.
Kurland, J. F.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 (05) : 448 - 457
[3] Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Sangro, B.
Kelley, R. K.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
De Toni, E. N.
Furuse, J.
Kang, Y-K.
Galle, P. R.
Rimassa, L.
Heurgue, A.
Tam, V. C.
Dao, T. V.
Thungappa, S. Chiradoni
Breder, V.
Ostapenko, Y. V.
Reig Monzon, M. E.
Gupta, C.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1530 - S1531
[4] Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yuriy
Heo, Jeong
Cheng, Ann-Lii
Vogel, Arndt
Marcovitz, Michelle
Abraham, Jayne
Patel, Nikunj
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
Kudo, Masatoshi
[J]. HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
[6] Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yurii
Heo, Jeong
Cheng, Ann-Lii
Woods, Andrea Wilson
Gupta, Charu
Abraham, Jayne
Mccoy, Carrie L.
Patel, Nikunj
Negro, Alejandra
Vogel, Arndt
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)
[7] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, L. S.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
[8] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[9] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[10] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466

← 1 2 3 4 5 →